Author: Vere Hodge, R Anthony
Title: Meeting report: 30th International Conference on Antiviral Research, in Atlanta, GA, USA Document date: 2018_6_28
ID: tudwns0r_6
Snippet: In a Phase I clinical study, PSI-6130 was well tolerated, there being no serious adverse events up to a dose of 9000 mg. The bioavailability was modest ($ 25%) and, encouragingly, there was only 10% conversion to the inactive uridine metabolite. In collaboration with Roche, a prodrug approach was started with the aim to increase bioavailability and, if possible, decrease the conversion to the uridine metabolite. This programme led to RG7128. In a.....
Document: In a Phase I clinical study, PSI-6130 was well tolerated, there being no serious adverse events up to a dose of 9000 mg. The bioavailability was modest ($ 25%) and, encouragingly, there was only 10% conversion to the inactive uridine metabolite. In collaboration with Roche, a prodrug approach was started with the aim to increase bioavailability and, if possible, decrease the conversion to the uridine metabolite. This programme led to RG7128. In a 14-day monotherapy Phase II study in HCV GT1 non-responder patients, there was a 2.7 log 10 reduction in HCV RNA levels. In a fourweek combination study (RG7128 (1000 or 1500 mg bid) with pegylated IFN and RBV), there was $ 90% response rate with safety comparable to the corresponding placebo control. Certainly, this was an encouraging result but the high doses and the twicedaily dosing regimen were of concern which were unlikely to be overcome by the prodrug approach. So was there another option? Why was the uridine metabolite (PSI-6206) inactive? The Pharmasset team decided to try a different approach.
Search related documents:
Co phrase search for related documents- adverse event and combination study: 1, 2, 3, 4, 5, 6
- adverse event and high dose: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- adverse event and Phase clinical study: 1, 2, 3
- adverse event and placebo control: 1, 2, 3, 4, 5, 6, 7, 8
- adverse event and response rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- bioavailability increase and clinical study: 1
- bioavailability increase and high dose: 1
- clinical study and combination study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35
- clinical study and different approach: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- clinical study and encouraging result: 1
- clinical study and high dose: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47
- clinical study and Phase clinical study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74
- clinical study and placebo control: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
- clinical study and response rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35
- combination study and different approach: 1, 2
- combination study and high dose: 1, 2, 3, 4, 5, 6
- combination study and Phase clinical study: 1, 2, 3
- combination study and response rate: 1, 2, 3, 4, 5, 6, 7, 8
Co phrase search for related documents, hyperlinks ordered by date